By Fineline Cube 
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with compatriot firm Shanghai Bao Pharmaceuticals Co., Ltd. Under the agreement, Anke Bio obtains exclusive commercialization rights in China (including Hong Kong, Macau, and Taiwan) for Bao Pharma’s innovative drug SJ02 (recombinant human follicle-stimulating hormone-CTP fusion protein, long-acting FSH-CTP).
Drug Profile and Mechanism
SJ02 is designed for controlled ovarian stimulation when combined with GnRH antagonists, enabling multi-follicular development. The drug requires only a single injection per ovulation induction cycle and maintains effective multi-follicular growth for up to seven days.
Market Significance
Currently under marketing review, SJ02 is poised to become China’s first approved long-acting follicle-stimulating hormone. This breakthrough treatment option in assisted reproductive technology (ART) holds significant market potential.-Fineline Info & Tech